Pfizer is the first big pharmaceutical company to reach an agreement with the Trump administration over most-favored nation drug pricing, a deal that lowers U.S. prices of certain medications and makes them available directly to patients through new online channels. The agreement announced Tuesday also gives Pfizer a grace period before facing potential tariffs on its drugs. With most-favored nation pricing, the prices of a drug in the U.S. will be matched to the lowest price of the same drug in a comparable developed nation.
He said that the administration has "some great people working on this project," but he would "give the program, and what we know, as of today, a grade of B." "Why not an A? The stock prices of PBMs didn't get crushed," wrote Cuban. "Which means, so far, no one expects much change for them. Which they expect they will make up lost revenues from patients, companies, and other payers elsewhere."